Our data demonstrate that a BsAb approach simultaneously blocking RANKL/RANK and the PD‐1/PD‐L1 immune checkpoint in the TME may provide a more effective immunotherapy approach strategy against cancers, including those that fail to respond to current ICI. Here, PDCD1 is linked to cancer.